Clinical Practice Guidelines (CPG) define the use of diagnostic, therapeutic and preventive modalities, including non-invasive and invasive procedures, in the management of patients with various liver diseases. They are intended to assist physicians and other healthcare providers ,as well as, patients and interested individuals in the clinical decision making process by describing a range of generally accepted approaches for the diagnosis, treatment and prevention of specific liver diseases. CPGs have to be distinguished from consensus statements and position papers.
Future guidelines (work in progress):
 |
EASL is pleased to announce the publication of its 9th Clinical Practice Guidelines (CPG) on the Management of Alcoholic Liver Disease. 
|
 |
April 2012, in the run-up to The International Liver Congress™ 2012, EASL releases revised CPGs on the Management of Chronic Hepatitis B originally released in October 2008... read more
|
 |
EASL is pleased to announce the publication of its 7th Clinical Practice Guidelines (CPG) on the Management of Hepatocellular Carcinoma.
|
 |
Developed to assist physicians and other healthcare providers in the diagnosis and management of patients with Wilson’s disease. The goal of these CPGs is to describe a number of generally accepted approaches for diagnosis, prevention, and treatment of Wilson’s disease.
|
 |
EASL is pleased to announce the publication of its 5th Clinical Practice Guidelines on the Management of Hepatitis C Virus Infection (June update).
|
 |
EASL is pleased to announce the publication of its 4th Clinical Practice Guidelines on the Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis.
|
 |
EASL is pleased to announce the publication of its 3rd Clinical Practice Guidelines on the Management of HFE Hemochromatosis (HFE-HC).
|
 |
In October 2008, EASL proudly published its first CPG on the Management of Chronic Hepatitis B. Eight months later, new subject matter was published in the same series of Clinical Practice Guidelines; this time on the Management of Cholestatic Liver Diseases.
|
 |
Worldwide, hepatitis B virus is a major cause of liver disease (acute and chronic hepatitis, cirrhosis and liver cancer). Approximately, 350 million individuals are infected.
|
